CK1α serves as an upstream regulator of the p53 pathway, and its degradation may facilitate cell death by preventing MDM2 and/or MDMX mediated inactivation of p53.
Orofacial clefting is a common birth defect that affects 1 in 700 newborns, and includes cleft lip, cleft palate and cleft lip and palate, with a strong genetic component, thus being highly heritable. Researchers have identified new gene variants tied to orofacial clefting.
Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.
4M Therapeutics Inc. has been awarded a $120,000 grant from SynGAP Research Fund (SRF) to evaluate central nervous system (CNS) effects of novel glycogen synthase kinase 3 β (GSK-3β) inhibitors 4MT-2001 and 4MT-1060.
CSPC Pharmaceutical Group Ltd.’s SYS-6026 has obtained clearance from China’s National Medical Products Administration (NMPA) to enter clinical trials for the treatment of high-grade squamous intraepithelial lesions associated with human papillomavirus (HPV) type 16 or 18.
At the annual meeting of the American Society for Human Genetics, scientists presented three new cases of Kabuki syndrome presented with developmental delay, autism and myopia as the common traits.
RSS
